KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Next earnings Jul 16, 2026 · consensus $-0.61 EPS, $27.0M rev
Last earnings +10.7% on 2026-03-17
$26.43
▲ +17.05%$26.43▲ +75.85%
over 1Y
L $14.46EODHDH $27.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+17.1%
1W+17.1%
1M+25.9%
3M+35.8%
YTD+8.4%
1Y+75.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Revenue grew 115.1% YoY; but unprofitable (net margin -190.3%).
KESTRA MEDICAL TECHNOLOGIES, LTD. shows $59.8M in FY2025 revenue (+115.1% YoY), a -190.3% net margin, and -55.4% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $27.8M | $59.8M |
| Gross profit | $362K | $24.2M |
| Operating income | -$85.1M | -$106M |
| Net income | -$94.1M | -$114M |
| Diluted EPS | -$5.07 | -$5.13 |
| Net margin | -338.4% | -190.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.16B
EV / EBITDA—
EV / Sales19.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-8.4%
FCF yield-7.4%
Quality & risk
ROIC (est.)-34.1%
Free cash flow-$101M
Total debt$41.1M
Net cash$196M
Altman Z-Score6.45 safe
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-15open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-05-152026-05-18open ↗144Filing2026-05-15open ↗4Period ending 2026-04-152026-04-16open ↗144Filing2026-04-15open ↗SCHEDULE 13G/AFiling2026-04-08open ↗
Frequently asked
- Is KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a buy?
- KMTS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 115.1% YoY; but unprofitable (net margin -190.3%).
- What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s quality score?
- KMTS scores 39.509803921568626/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001877184, latest 10-Q filed 2026-03-17) · EODHD · as of 6/26/2026, 7:00:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.